Asia
In a filing with the court, Seattle Genetics claimed the right to arbitration to resolve the dispute with Daiichi Sankyo, as is required by the 2008 collaboration agreement.
MaxQ AI’s ACCIPIO® ICH and Stroke platform will be integrated into the next generation of GE Healthcare’s PACS and Universal Viewing platforms
TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, has been invited by MasterLink Securities to hold an investor conference on December 6, 2019.
Utilizing AI technology to streamline information analysis and contribute to progress in an emergent, yet vital frontier of medical science
ASLAN announced positive preliminary data from the lowest dose cohort of its ongoing multiple ascending dose study of ASLAN004, which is aimed at moderate-to-severe atopic dermatitis.
There are many challenges to tackling neurological diseases like Alzheimer’s, but one is the difficulty in developing drugs that can cross the blood-brain barrier. Researchers may have found a way around that problem.
Eisai Co., Ltd. has announced that the latest data on its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 73rd American Epilepsy Society Annual Meeting (AES 2019) to be held from December 6 to December 10, 2019 in Baltimore, Maryland in the United States.
Even with a shortened week due to the U.S. Thanksgiving holiday, there was plenty of clinical trial news and updates. Here’s a look.
Companies from across the globe provide updates on their businesses and pipelines.
TauRx analyzed the relationship between the treatment doses, blood levels and pharmacological activity of the drug on the brain in more than 1,000 patients with mild-to-moderate Alzheimer’s disease as part of two Phase III global clinical trials.
PRESS RELEASES